Startup · $1.5m raised
Developing an mRNA vaccine against Epstein–Barr virus.
Every investor coverage indicates participated in a round Ebivanta Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Biointelect Venturer | Accelerator | - |
Companies Ebivanta Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Ebivanta Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
QIMR Berghofer's Ebivanta Therapeutics wins $1.5 million plus backing from biotech incubator Biointelect Venturer's first cohort to ready its mRNA vaccine against Epstein-Barr virus for clinical testing.
An Australian infectious-disease incubator has selected six local biotechs to divide $10.48 million from its inaugural funding round, pairing non-dilutive cash with commercialisation support; the program is backed by an earlier MRFF grant.